The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of Which non FDA (United States Food and Drug Administration) approved peptides, such as BPC 157 (Body Protection Compound 157) and TB 500 (Thymosin Beta 500), are likely legitimate for medical use under strict supervision? Peptides! Update as of 4.15.26 from the FDA. We will know more in July. This will allow these previously labeled category 2 research peptides to category 1 and allowable for compounding by